New insights on the potential anti‐epileptic effect of metformin: Mechanistic pathway

• Published in: Journal of cellular and molecular medicine Vol. 27; no. 24; pp. 3953 - 3965
• Main Authors: Alnaaim, Saud A., Al‐kuraishy, Hayder M., Al‐Gareeb, Ali I., Ali, Naif H., Alexiou, Athanasios, Papadakis, Marios, Saad, Hebatallah M., Batiha, Gaber El‐Saber
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01-12-2023; John Wiley and Sons Inc
• Subjects: Adenosine kinase; Alzheimer's disease; AMP; Antidiabetics; Brain injury; Brain-derived neurotrophic factor; Convulsions & seizures; Cytokines; Developing countries; Diabetes; Diabetes mellitus; Disease; Drug interactions; Epilepsy; Hyperglycemia; Inflammation; Insulin; Kinases; LDCs; Metformin; Mutation; Neurological diseases; Neuromodulation; Neuroprotection; Phosphoprotein phosphatase; Protein phosphatase; Rapamycin; Review; Reviews; seizure; Seizures; Signal transduction; Synuclein; TOR protein; epilepsy; metformin; seizure
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.17965

Epilepsy is a chronic neurological disease characterized by recurrent seizures. Epilepsy is observed as a well‐controlled disease by anti‐epileptic agents (AEAs) in about 69%. However, 30%–40% of epileptic patients fail to respond to conventional AEAs leading to an increase in the risk of brain structural injury and mortality. Therefore, adding some FDA‐approved drugs that have an anti‐seizure activity to the anti‐epileptic regimen is logical. The anti‐diabetic agent metformin has anti‐seizure activity. Nevertheless, the underlying mechanism of the anti‐seizure activity of metformin was not entirely clarified. Henceforward, the objective of this review was to exemplify the mechanistic role of metformin in epilepsy. Metformin has anti‐seizure activity by triggering adenosine monophosphate‐activated protein kinase (AMPK) signalling and inhibiting the mechanistic target of rapamycin (mTOR) pathways which are dysregulated in epilepsy. In addition, metformin improves the expression of brain‐derived neurotrophic factor (BDNF) which has a neuroprotective effect. Hence, metformin via induction of BDNF can reduce seizure progression and severity. Consequently, increasing neuronal progranulin by metformin may explain the anti‐seizure mechanism of metformin. Also, metformin reduces α‐synuclein and increases protein phosphatase 2A (PPA2) with modulation of neuroinflammation. In conclusion, metformin might be an adjuvant with AEAs in the management of refractory epilepsy. Preclinical and clinical studies are warranted in this regard.